| Christopher L Davis, DO | |
|
3225 W Gordon Ave, Ste 1, Layton, UT 84041-6508 | |
| (801) 397-6150 | |
| (801) 397-6151 |
| Full Name | Christopher L Davis |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 14 Years |
| Location | 3225 W Gordon Ave, Layton, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346565561 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 8138568-1204 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Davis Hospital And Medical Center | Layton, UT | Hospital |
| Layton Hospital | Layton, UT | Hospital |
| Ogden Regional Medical Center | Ogden, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ogden Clinic Pc | 9638078033 | 88 |
News Archive
Percepta Associates Inc. announces the release of Series Three of its Gene Expression Profiling Life Science Dashboard market research report. Unique to the Percepta report, Series Three offers comparisons to the findings of Series One (February 2007) and Series Two (April 2008).
Long-term data from an investigational study of Deep Brain Stimulation (DBS) Therapy for Epilepsy was released this week by Medtronic, Inc. (NYSE:MDT) at the American Epilepsy Society Meeting (AES) in Boston.
Rice University chemists have discovered a way to load dozens of molecules of the anti-cancer drug paclitaxel onto tiny gold spheres. The result is a tiny ball, many times smaller than a living cell that literally bristles with the drug.
A journey into the places, people, and decisive moments that made the men who are competing for the presidency. ...As governor, Romney knew he needed what political pros called a "legacy issue" if he wanted to run for president one day. He devoted his energy towards reforming health care, an issue that Democrats had been grappling with and a problem that cost the state dearly as taxpayers bore the brunt of covering the uninsured.
MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
› Verified 6 days ago
| Entity Name | Ogden Clinic Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578550083 PECOS PAC ID: 9638078033 Enrollment ID: O20040105000780 |
News Archive
Percepta Associates Inc. announces the release of Series Three of its Gene Expression Profiling Life Science Dashboard market research report. Unique to the Percepta report, Series Three offers comparisons to the findings of Series One (February 2007) and Series Two (April 2008).
Long-term data from an investigational study of Deep Brain Stimulation (DBS) Therapy for Epilepsy was released this week by Medtronic, Inc. (NYSE:MDT) at the American Epilepsy Society Meeting (AES) in Boston.
Rice University chemists have discovered a way to load dozens of molecules of the anti-cancer drug paclitaxel onto tiny gold spheres. The result is a tiny ball, many times smaller than a living cell that literally bristles with the drug.
A journey into the places, people, and decisive moments that made the men who are competing for the presidency. ...As governor, Romney knew he needed what political pros called a "legacy issue" if he wanted to run for president one day. He devoted his energy towards reforming health care, an issue that Democrats had been grappling with and a problem that cost the state dearly as taxpayers bore the brunt of covering the uninsured.
MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher L Davis, DO Po Box 5546, Denver, CO 80217-5546 Ph: (801) 397-6150 | Christopher L Davis, DO 3225 W Gordon Ave, Ste 1, Layton, UT 84041-6508 Ph: (801) 397-6150 |
News Archive
Percepta Associates Inc. announces the release of Series Three of its Gene Expression Profiling Life Science Dashboard market research report. Unique to the Percepta report, Series Three offers comparisons to the findings of Series One (February 2007) and Series Two (April 2008).
Long-term data from an investigational study of Deep Brain Stimulation (DBS) Therapy for Epilepsy was released this week by Medtronic, Inc. (NYSE:MDT) at the American Epilepsy Society Meeting (AES) in Boston.
Rice University chemists have discovered a way to load dozens of molecules of the anti-cancer drug paclitaxel onto tiny gold spheres. The result is a tiny ball, many times smaller than a living cell that literally bristles with the drug.
A journey into the places, people, and decisive moments that made the men who are competing for the presidency. ...As governor, Romney knew he needed what political pros called a "legacy issue" if he wanted to run for president one day. He devoted his energy towards reforming health care, an issue that Democrats had been grappling with and a problem that cost the state dearly as taxpayers bore the brunt of covering the uninsured.
MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
› Verified 6 days ago
Dr. Douglas Paul Barney, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2132 North 1700 West, Suite 100, Layton, UT 84041 Phone: 801-807-7900 Fax: 801-807-7904 | |
Michael Dayton Delange, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3225 W Gordon Ave Ste 1, Layton, UT 84041 Phone: 801-397-6150 Fax: 801-397-6151 | |
Dr. Casey Lawrence Stelter, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2940 N Church St, Layton, UT 84040 Phone: 801-475-3010 Fax: 801-475-3001 | |
Dr. Johnnie V Cook, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2075 N 1200 W, Layton, UT 84041 Phone: 801-779-6200 | |
Marc O Anderson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2121 No 1700 W, Layton, UT 84041 Phone: 801-773-4840 Fax: 801-525-8151 | |
Ted H Burningham, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2121 N 1700 W, Layton, UT 84041 Phone: 801-773-4840 Fax: 801-525-8187 | |
Dr. Mark K Milligan, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2075 N 1200 W, Layton, UT 84041 Phone: 801-779-6200 |